IRIS
PITINI, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.032
EU - Europa 2.435
AS - Asia 775
SA - Sud America 5
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 6.253
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.029
IE - Irlanda 706
SE - Svezia 682
CN - Cina 457
UA - Ucraina 335
SG - Singapore 284
DE - Germania 217
GB - Regno Unito 133
FI - Finlandia 125
IT - Italia 106
BE - Belgio 39
RU - Federazione Russa 29
IN - India 18
CZ - Repubblica Ceca 16
FR - Francia 15
AT - Austria 11
NL - Olanda 8
IR - Iran 5
BR - Brasile 3
HK - Hong Kong 3
IL - Israele 3
JP - Giappone 3
NO - Norvegia 3
CA - Canada 2
EU - Europa 2
LV - Lettonia 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AR - Argentina 1
AU - Australia 1
CL - Cile 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
ID - Indonesia 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
SC - Seychelles 1
Totale 6.253
Salva come PNG Salva come JPEG
Città #
Dublin 706
Jacksonville 651
Chandler 567
Nyköping 358
Singapore 237
Beijing 204
Ashburn 161
Ann Arbor 156
Princeton 123
Cambridge 119
Des Moines 100
Dearborn 93
Medford 86
Boardman 70
Lancaster 61
Woodbridge 60
Messina 54
New York 40
Wilmington 39
Brussels 37
Jinan 34
Los Angeles 30
Shenyang 26
Munich 22
San Mateo 22
Tianjin 22
Seattle 20
Houston 19
Ningbo 17
Brno 16
Nanjing 16
Haikou 14
Nanchang 14
Zhengzhou 14
Auburn Hills 13
Taizhou 13
Hebei 12
Vienna 11
Hangzhou 10
Guangzhou 8
Hyderabad 8
Pune 8
Bremen 7
Norwalk 7
Washington 7
Changsha 6
Chicago 6
Lanzhou 5
Leawood 5
Monmouth Junction 5
Santa Clara 5
Catania 4
Clearwater 4
Edinburgh 4
Helsinki 4
Las Vegas 4
Taiyuan 4
Bologna 3
Jiaxing 3
Kemerovo 3
Naples 3
Novokuznetsk 3
Oslo 3
Redwood City 3
Riva 3
Saint Petersburg 3
Scarsdale 3
Amsterdam 2
Charlottesville 2
Dallas 2
Florence 2
Floridia 2
Fuzhou 2
Joinville 2
Lappeenranta 2
Milan 2
Montebelluna 2
Polomka 2
Santiago 2
Shanghai 2
Tappahannock 2
Tokyo 2
Trani 2
Uggiate Trevano 2
Waanrode 2
Apo 1
Atlanta 1
Auckland 1
Baotou 1
Budapest 1
Buenos Aires 1
Central 1
Chengdu 1
Chongqing 1
Eden Prairie 1
Gaithersburg 1
Gostar 1
Groningen 1
Gurugram 1
Hanover 1
Totale 4.449
Salva come PNG Salva come JPEG
Nome #
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 99
Emerging markers of cachexia predict survival in cancer patients. 92
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 89
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 88
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas 86
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 84
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 82
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 78
Trattamento endoscopico scleroterapico nelle neoplasie sanguinanti del tratto digestivo. 77
CLINICAL ACTIVITY OF BORTEZOMIB IN RELAPSED OR REFRACTORY GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT TYPE 76
An accessory spleen wrongly recognised as relapse by positron emission tomography 74
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 74
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 72
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 69
AMIFOSTINE IN CONJUCTION WITH H.D. VP16 AND G-CSF ENABLE PBSC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 69
An acute-leukaemia-like picture due to breast carcinoma cells. 68
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 68
Effect of treatment with amifostine in patients with myelodisplastic syndromes on clinical outcome and apoptosis in bone marrow 67
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 66
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes 66
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 66
IMATINIB-INDUCED APOPTOSIS IN EOSINOPHILS OF PATIENTS WITH A HYPEREOSINOPHILIC SYNDROME PREDICTS RESPONSE TO TREATMENT 65
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 65
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma 65
OUR EXPERIENCE ON THE EFFECTS OF TAMOXIFEN ON BLOOD COAGULATION IN PATIENTS OPERATED FOR BREAST CANCER Folia Oncologica vol.XIV-n.2-3 (Aprile-Settembre)-1991 64
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report 64
IMMUNOCHEMOTHERAPY WITH RITUXIMAB AND TEMOZOLOMIDE FOR CENTRAL NERVOUS SYSTEM LYMPHOMAS 63
A sequential chemoimmunotherapy protocol can obtain a high proportion of molecular remission in chronic lymphocytic leukaemia 63
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 63
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 63
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 63
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 62
Fatal delayed diagnosis in a patient with falciparum malaria 61
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 60
Thyroid function, autoimmunity and nodules in hematological malignancies 60
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 59
MORPHOLOGICAL, PHENOTYPIC AND KARYOTYPIC CHARACTERIZATION OF A NOVEL NATURAL-KILLER-CELL TARGET - EVIDENCE OF INVOLVEMENT OF MHC CLASS-I MOLECULES IN NK CELL RECOGNITION 59
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 59
Endobronchial electrocautery for the dehydration of lung cancer. 59
Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study 58
AN UNUSUAL PRESENTATION OF SCHISTOSOMIASIS 58
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 57
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 57
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 57
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 57
ANCHE IN VIVO IL PAMIDRONATO E' UN INDUTTORE DELLA APOPTOSI NELLE PLASMACELLULE MIELOMATOSE 57
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients 56
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease 55
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 55
Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a patient with breast cancer 55
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 55
Single-dose pegfilgrastim after chemotherapy is sufficient for mobilisation of peripheral blood stem cells in patients with multiple myeloma 54
Circulating plasma cells in Multiple Myeloma: correlation with disease stage 54
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 53
GENE EXPRESSION PROFILING DOES NOT IDENTIFY MOLECULAR SUBGROUP AMONG NODAL PERIPHERAL T-CELL LYMPHOMAS 52
Uso di Bortezomib come terapia di prima linea nella leucemia plasmacellulare primaria 52
DIABETIC FOOT DISEASE IN A PATIENT WITH MULTIPLE MYELOMA RECEIVING THALIDOMIDE 51
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report 51
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient 51
Temozolomide-induced shrinkage of a pituitary carcinoma. 51
SUCCESSFULL MOBILIZATION OF PERIPHERAL PROGENITOR CELLS WITH PACLITAXEL AND LENOGRASTIM PATIENTS WITH METASTATIC BREAST CANCER 50
ALTE DOSI: QUESTIONI APERTE E SVILUPPI FUTURI 50
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 50
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 50
Use of bisphosphonates in oncology 50
IMPIEGO DELLA AMIFOSTINA NELLE PROCEDURE DI MOBILIZZAZIONE. NOSTRA ESPERIENZA 49
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 49
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 49
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 49
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 49
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence 48
Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population. 48
ADVERSE PROGNOSTIC FACTOR OF p53 GENE DELECTION DETECTED BY FISH IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION 48
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 48
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 48
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 48
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF 48
ERYTHROPOIETIN IN COMBINATION WITH LENOGRASTIM AFTER CYCLOPHOSPHAMIDE IMPROVES PERIPHERAL BLOOD PROGENITOR CELL YIELD IN MULTIPLE MYELOMA PATIENT 47
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 47
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 47
Single-dose of pegfilgrastim after chemotherapy is sufficient for mobilization of peripheral blood stem cells in patients with multiple myeloma 46
IMPIEGO DELLA AMIFOSTINE+HD VP16+G-CSF NEI PAZIENTI CON MIELOMA MULTIPLO CHE NON MOBILIZZANO DOPO CTX+G-CSF 46
Pitfalls of positron emission tomography for assessing relapse in Hodgkin'sdisease: a case report 46
Sequential treatment with alemtuzumab and rituximab can induce long-term responses in splenic marginal zone lymphoma 46
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 46
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 45
How cells respond to interferons. 45
Risk of second malignant neoplasm among patients with lymphoma 45
ANALISI SEQUENZIALE DELLA TRISOMIA 12 NELLA LEUCEMIA LINFATICA CRONICA 44
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate. 44
Efficacy and safety of bortezomib in patients with plasma cell leukemia 44
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 44
PIK3CA mutations in breast cancer: A potential predictive marker 43
LONG-TERM RESULTS FROM MOPPEBVCAD CHEMOTHERAPY WITH OPTIONAL LIMITED RADIOTHERAPY IN ADVANCED HODGKIN'S DISEASE 43
RESPONSE TO IMATINIB IN CHRONIC MYELOPROLIFERATIVE DISEASES WITH ACTIVATION OF THE PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR (PDGF betaR) 41
BORTEZOMIB AND PLASMA CELL LEUKEMIA 41
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 41
MOPP EBV CAD HYBRID CHEMOTHERAPY WITH OR WITHOUT LIMITED RADIOTHERAPY IN ADVANCED OR UNFAVORABLY PRESENTING HODGKINS- DISEASE - A REPORT FROM THE ITALIAN-LYMPHOMA-STUDY-GROUP 40
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 40
NON HODGKIN’S LYMPHOMAS RADIOIMMUNOTHERAPY: PERSONAL EXPERIENCE 38
Totale 5.713
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.351
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.351
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020663 0 0 0 0 7 78 145 117 9 163 140 4
2020/2021767 118 4 199 36 32 96 8 84 16 89 57 28
2021/2022848 6 139 18 17 25 3 58 27 5 160 154 236
2022/20232.164 173 209 102 170 187 205 23 136 855 9 71 24
2023/2024445 38 88 29 57 28 83 14 34 3 22 3 46
2024/2025328 28 34 31 145 90 0 0 0 0 0 0 0
Totale 6.376